Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.

× No keyword cloud information.

17 in total

1. N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.

Authors: Aleem Gangjee; Nilesh Zaware; Sudhir Raghavan; Jie Yang; Jessica E Thorpe; Michael A Ihnat
Journal: Bioorg Med Chem Date: 2012-02-04 Impact factor: 3.641

2. Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case.

Authors: Fumihiro Shoji; Daigo Kawano; Kensaku Ito; Yosuke Morodomi; Tokujiro Yano; Yoshihiko Maehara
Journal: Surg Today Date: 2011-01-26 Impact factor: 2.549

3. Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents.

Authors: Aleem Gangjee; Nilesh Zaware; Sudhir Raghavan; Bryan C Disch; Jessica E Thorpe; Anja Bastian; Michael A Ihnat
Journal: Bioorg Med Chem Date: 2013-01-31 Impact factor: 3.641

4. EGFR-TKI-induced HSP70 degradation and BER suppression facilitate the occurrence of the EGFR T790 M resistant mutation in lung cancer cells.

Authors: Xiang Cao; Yi Zhou; Hongfang Sun; Miao Xu; Xiaowen Bi; Zhihui Zhao; Binghui Shen; Fengyi Wan; Zhuan Hong; Lei Lan; Lan Luo; Zhigang Guo; Zhimin Yin
Journal: Cancer Lett Date: 2018-03-07 Impact factor: 8.679

5. The Lake Wobegon effect: are all cancer patients above average?

Authors: Jacqueline H Wolf; Kevin S Wolf
Journal: Milbank Q Date: 2013-12 Impact factor: 4.911

6. Management of patients with advanced non-small cell lung cancer: role of gefitinib.

Authors: Vamsidhar Velcheti; Daniel Morgensztern; Ramaswamy Govindan
Journal: Biologics Date: 2010-05-25

7. Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study.

Authors: G P Stathopoulos; D Trafalis; J Dimitroulis; A Athanasiou; J Koutantos; A Anagnostopoulos
Journal: Oncol Lett Date: 2010-03-01 Impact factor: 2.967

8. N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents.

Authors: Aleem Gangjee; Ojas A Namjoshi; Jianming Yu; Michael A Ihnat; Jessica E Thorpe; Lora C Bailey-Downs
Journal: Bioorg Med Chem Date: 2013-01-10 Impact factor: 3.641

Review 9. Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.

Authors: Orit Jacobson; Xiaoyuan Chen
Journal: Pharmacol Rev Date: 2013-09-24 Impact factor: 25.468

10. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.

Authors: Aleem Gangjee; Ojas A Namjoshi; Jianming Yu; Michael A Ihnat; Jessica E Thorpe; Linda A Warnke
Journal: Bioorg Med Chem Date: 2008-04-14 Impact factor: 3.641